Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.

@article{Njar2015DiscoveryAD,
  title={Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.},
  author={Vincent C. O. Njar and Angela M. H. Brodie},
  journal={Journal of medicinal chemistry},
  year={2015},
  volume={58 5},
  pages={2077-87}
}
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase (CYP17), the key enzyme which catalyzes the biosynthesis of androgens from progestins, 3β-(hydroxy)-17-(1H-benzimidazole-1-yl)androsta-5,16-diene (Galeterone or TOK-001, formerly called VN/124-1) was identified as a selective development candidate which modulates multiple targets in the androgen receptor (AR) signaling pathway. This drug annotation summarizes the mechanisms of action, scientific rationale… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
Discovery and development of Galeterone ( TOK-001 or VN/124 - 1 ) for the treatment of all stages of prostate cancer .
Discovery and development of Galeterone ( TOK-001 or VN/124 - 1 ) for the treatment of all stages of prostate cancer .
In our effort to discover potent and specific inhibitors of 17α-hydroxylase/17,20-lyase ( CYP17 ) , the key enzyme which catalyzes the biosynthesis of androgens from progestins , 3β-(hydroxy)-17-(1H - benzimidazole-1-yl)androsta-5,16-diene ( Galeterone or TOK-001 , formerly called VN/124 - 1 ) was identified as a selective development candidate which modulates multiple targets in the androgen receptor ( AR ) signaling pathway .
All Topics